| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| BioNTech SE | Pumitamig - (China trial/ROSETTA HCC-206) | 1L HCC | Phase 2 | Ongoing | Intravenous | Oncology |
| BioNTech SE | Pumitamig - (ROSETTA Lung-01) | 1L ES-SCLC | Phase 2 | Ongoing | Intravenous | Oncology |
| BioNTech SE | BNT162b5 | COVID-19 vaccine | Phase 2 | Intramuscular | COVID-19 | |
| BioNTech SE | Gotistobart (BNT316/ONC-392) with lutetium Lu 177 vipivotide tetraxetan (Lu 177) | Metastatic castration-resistant prostate cancer (mCRPC) | Phase 2 | Ongoing | Intravenous | Oncology |
| BioNTech SE | Pumitamig | 1L HER2- PD-L1+ gastric cancer | Phase 3 | Trial Planned | Intravenous | Oncology |
| BioNTech SE | BNT327/PM8002 with chemotherapy | Triple negative breast cancer | Phase 3 | IND Clearance | Intravenous | Oncology |
| BioNTech SE | Autogene cevumeran (BNT122/RO7198457) - (IMCODE004) | High-risk muscle-invasive urothelial carcinoma (MIUC) | Phase 3 | Enrollment Initiation | Intravenous | Oncology |
| BioNTech SE | BNT323/DB-1303 | Advanced endometrial cancer | Phase 3 | Ongoing | Intravenous | Oncology |